# Danh sách chất
1. 3-((4H-benzo[d][1,3,2]dioxaborinin-2-yl)methyl)-1-(4-(benzyloxy)-3-methoxybenzyl)-2-methoxy-1,2-azaborolidine

2. 2-((2-methoxy-2,3-dihydrobenzo[d][1,2]oxaborol-3-yl)methyl)-4H-benzo[d][1,3,2]dioxaborinine

# Đích

# **1. PPARA (7BQ2)** `A:273, A:275, A:276, A:279`

### 🌟 4 Axit amin linh động BẮT BUỘC (Literature-Verified Tier)
Nhóm này giải quyết trực tiếp vấn đề chênh lệch kích thước (size-mismatch) để 2 chất của bạn có thể lọt được vào túi Arm III:

1. **Phe273 (Phenylalanine 273):** Đóng vai trò là "người gác cổng" (gatekeeper). Nó bắt buộc phải được phép lật/xoay (flip) để tạo khoảng trống cho cái đuôi *benzyloxy* rất dài của chất thứ nhất chui vào sâu trong túi kỵ nước.
2. **Cys275 (Cysteine 275)** và 
3. **Cys276 (Cysteine 276):** Đây là hai bản lề cơ học (mechanical hinges) của túi gắn kết PPARα. Việc cài đặt linh động 2 gốc này cho phép toàn bộ cấu trúc túi (LBD) phình to ra một cách tự nhiên để ôm trọn cấu trúc lõi *dioxaborinine* cồng kềnh của cả 2 chất. Nếu để cứng (rigid), phần mềm sẽ báo lỗi va chạm (steric clash).
4. **Thr279 (Threonine 279):** Đây là mỏ neo (anchor) cực kỳ quan trọng nằm sâu trong nhánh **Arm III**. Cấu trúc của Thr279 rất linh hoạt và sẽ tự động xoay để tạo liên kết hydro (trực tiếp hoặc qua cầu nối nước) với các nguyên tử O, N, B trên lõi phân tử của bạn, từ đó quyết định hoạt lực và độ chọn lọc cực cao.

# **2. PPARD (7WGN)** `A:253, A:287, A:413, A:437`

**Layer 1 — Core Insight**
Designing multi-target boronic ligands presents a topological challenge when navigating the promiscuous peroxisome proliferator-activated receptor (PPAR) ligand-binding domains. The 7WGN co-crystal structure demonstrates that pemafibrate binds the Y-shaped Center and Arm II/III regions of PPAR delta. To achieve efficacy, your size-mismatched azaborolidine and dioxaborinine molecules must satisfy the specific consensus hydrogen-bond network of PPAR delta while structurally displacing the spatial volume near helix 5.

**Layer 2 — Structural Explanation**
The literature does not explicitly classify discrete residues as "flexible" within the 7WGN dataset. We execute an adaption-tier protocol to define the obligatory dynamic coordinates for your bulky structures. First, your models must establish local plasticity at the consensus tetrad: Thr253, His287, His413, and Tyr437. These residues act as adaptive anchors that secure the ligand headgroup to stabilize the AF-2 helix 12. Second, structural accommodation in PPAR delta explicitly requires shifting the phenoxyalkyl-equivalent groups toward helix 5. Third, the binding pocket utilizes a water-mediated hydrogen bond or electrostatic interaction to stabilize the 2-aminobenzoxazole group. You must configure your docking grids to allow spatial adjustments at these precise locations to prevent steric clashes with your expansive benzyloxy and oxaborole units.

**Layer 3 — Full Technical Detail**

*External Map:* Fibrate cross-reactivity redefines therapeutic boundaries. Repurposing these molecules bridges dyslipidemia treatments directly to non-alcoholic fatty liver disease interventions. 
*Internal Map:* Receptor activation strictly requires aligning the ligand head with the AF-2 helix 12 consensus tetrad. Concurrently, the hydrophobic tail must occupy the specified Y-shaped Arm II/III geometry.

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **Pemafibrate functions as a structural pan-agonist across PPAR subtypes.** | Pemafibrate activates PPAR delta/gamma LBD-mediated transactivation, recruits coactivators, and physically binds PPAR delta/gamma LBDs. |, | High | Biochemical transactivation and co-crystallization successfully translate into physiological pan-agonism. | Pemafibrate requires concentrations three orders of magnitude higher to activate PPAR delta/gamma compared to PPAR alpha. |
| **PPAR delta imposes a unique spatial orientation on specific ligand substituents.** | In the 7WGN structure, the phenoxyalkyl group of pemafibrate is specifically pushed toward helix 5 within the PPAR delta pocket. | | High | Spatial deviation toward helix 5 is mandatory to resolve steric limitations unique to the delta subtype. | The fundamental Y-shaped binding geometry across the Center and Arm II/III regions remains largely identical across all three PPAR subtypes. |
| **AF-2 helix 12 stabilization requires a strict four-residue consensus network.** | Carboxylic groups stabilize AF-2 helix 12 formation through direct hydrogen bonds and electrostatic interactions with Thr253, His287, His413, and Tyr437 in PPAR delta. | | High | Boronic or carboxylic warheads must coordinate this exact tetrad to induce coactivator recruitment. | Fenofibric acid stabilizes PPAR delta thermostability but fails to functionally activate the receptor or produce cocrystals. |
| **Ligand efficacy demands hydrophobic interactions within the core pockets.** | Pemafibrate is further stabilized by extensive hydrophobic interactions within the LBDs of all PPARs. |, | Medium | Hydrophobic packing provides the primary thermodynamic driving force for complex formation. | Water-mediated hydrogen bonds actively participate in anchoring specific functional groups in PPAR delta. |

**Synthesis:** 
Modulating coordinate flexibility at the consensus tetrad dictates the boundary between partial agonism and highly selective receptor activation. The lack of specific structural flexibility forces compounds into inactive conformations. Fenofibric acid increases PPAR delta thermostability but fails to recruit coactivators, proving that simple binding does not guarantee functional activation. 

**Dispositive Closure:** 
When docking your 1,2-azaborolidine and dioxaborinine derivatives against 7WGN, you must mandate side-chain flexibility for Thr253, His287, His413, and Tyr437. You must direct your structural appendages toward the space bounded by helix 5. Failure to model this specific plasticity will yield false-negative collision errors.

# **3. PPARG (8ATY)** `A:288,A:342,A:259`

Traditional PPARγ therapeutics encounter a biological paradox. Maximal insulin sensitization intrinsically couples with severe pro-adipogenic adverse effects. Resolving this requires shifting focus toward noncanonical allosteric modulation. Topologically, the receptor achieves this via a secondary solvent-exposed cleft bounded by Helix 4, Helix 5, and the Omega loop. 

The conventional premise dictates that PPARγ activation strictly requires direct physical coordination of the Helix 12 AF-2 surface. This position fails because crystallographic evidence (PDB: 8ATZ) demonstrates that alternative site ligands stabilize the active Helix 12 conformation allosterically through the Omega-loop, entirely bypassing direct AF-2 contact. This conclusion would be invalidated if structural variants of your bulky azaborolidines fully occlude the orthosteric pocket while generating classical pro-adipogenic transcriptional profiles.

To properly dock your large 1,2-azaborolidine and dioxaborinine derivatives, you must target the alternative binding site. Static algorithms will fail to capture the required binding volume. You must implement the following literature-verified flexible residues.

### Literature-Tier Flexible Residues

1. **Arg288**: Acts as the primary electrostatic anchor in the alternative site. It dynamically shifts to form direct ionic interactions or water-mediated hydrogen bonds with polar moieties, such as boronic or oxaborole oxygen atoms.
2. **Ser342**: Provides essential backbone and side-chain hydrogen bonding. It shifts to stabilize complex aromatic extensions within the alternative pocket cleft.
3. **Glu259**: Regulates the solvent-exposed periphery. Its side chain establishes critical hydrogen bonds with secondary amines or ether oxygen linkers spanning the alternative pocket.
4. **Ser289, His449, and Tyr473**: The classical orthosteric triad. If your compounds exhibit multi-site occupancy (1:2 stoichiometry like JP85/Compound 1 in PDB 8ATY), these residues must adapt to stabilize the canonical interactions.

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence (Low/Medium/High) | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **PPARγ accommodates simultaneous multi-ligand occupancy across distinct sites.** | The LBD permits orthosteric ligands (pioglitazone) and alternative site ligands (Compound 2) to bind concurrently (1:1:1 stoichiometry) without steric competition. | Arifi et al., 2023 | High | Concurrent binding generates synergistic allosteric stabilization rather than independent silent states. | Specific extended ligands (MRL-871) occupy boundary regions overlapping both pockets, blocking secondary ligand entry. |
| **Helix 12 (AF-2) stabilization does not require direct orthosteric contact.** | Compound 2 induces an active Helix 12 state solely through alternative site binding, likely propagated via Omega-loop stabilization. | Arifi et al., 2023 | High | Omega-loop ordering mechanically couples to Helix 12 inward dynamics. | Alternative site ligands like BVT.13 bind the pocket but fail to trigger the active Helix 12 inward swing. |
| **Selective alternative site modulation prevents canonical adipogenesis.** | Targeting the H4/H5 cleft avoids the classical pro-adipogenic gene transcription profiles (e.g., CPT-1, FABP1) triggered by TZD therapies. | Arifi et al., 2023 | High | *In vivo* cellular differentiation pathways directly mirror these *in vitro* mRNAseq hepatocyte profiles. | The alternative site ligand still retains baseline recruitment of select canonical co-activators like PGC-1α. |
| **Alternative site activation uniquely suppresses FOXO signaling.** | The noncanonical binding mode diminishes FOXO3 expression and enhances inactivating Ser253 phosphorylation, driving cells toward a resting state. | Arifi et al., 2023 | Medium | FOXO suppression operates exclusively through genomic PPARγ regulation rather than secondary kinase off-targets. | Orthosteric PPARγ agonists like pioglitazone exert zero regulatory influence on this specific FOXO pathway. |

**Dispositive Closure:**
Configure your docking grid to explicitly encompass the Helix 4/Helix 5 cleft. Mandate side-chain flexibility for Arg288, Glu259, and Ser342. Evaluate your boronic poses based on their ability to stabilize the Omega loop rather than relying exclusively on direct Helix 12 contacts. This topology defines the absolute boundary between classical adipogenesis and selective noncanonical modulation.

# 4. EGFR (1XKK) `A:742, A:753, A:766, A:830, A:832, A:834`

Designing kinase inhibitors with extended benzyloxy appendages presents a profound steric paradox when targeting the canonically narrow active state of the epidermal growth factor receptor (EGFR). 

**Layer 1 — Core Insight**
The 1XKK crystal structure demonstrates that bulky inhibitors resolve this geometrical paradox by stabilizing a distinct inactive conformation of the kinase. This conformation features a massively expanded back pocket generated by a ~9 Å spatial shift of the C-helix. To achieve valid binding poses for your extended azaborolidine and dioxaborinine derivatives, algorithms must exploit this specific inactive topology.

**Layer 2 — Structural Explanation (Adaption-Tier Flexible Residues)**
The crystallographic literature does not explicitly catalog residues as computationally "flexible," mandating an adaption-tier protocol to define the dynamic boundaries for your large molecules. The 3-fluorobenzyloxy group of GW572016 (Lapatinib) physically forces the C-helix outward, creating a deep hydrophobic cavity. Your 4-(benzyloxy)-3-methoxybenzyl moiety demands this exact volumetric expansion to bind successfully. Consequently, docking protocols must assign side-chain plasticity to the specific residues lining this expanded back pocket. We identify Met742, Leu753, Thr766, Thr830, Phe832, and Leu834 as mandatory flexible coordinates. Furthermore, the outward displacement of the C-helix abolishes the highly conserved Glu738-Lys721 salt bridge, forcing Lys721 to coordinate directly with Asp831 in the lower lobe. Supplying flexibility to the Lys721 and Asp831 side-chains ensures the docking algorithm can model this disrupted electrostatic network without triggering artifactual collision penalties. 

**Layer 3 — Full Technical Detail**

*External Map:* 
In the broader therapeutic landscape, the dissociation half-life fundamentally dictates clinical efficacy. Inhibitors adopting the 1XKK inactive conformation exhibit a remarkably slow off-rate, quantified at 0.0023 per minute, yielding a complex half-life of 300 minutes. This slow dissociation sustains profound receptor down-regulation in tumor cells up to 96 hours after initial exposure, far surpassing the recovery rate observed with active-state inhibitors like OSI-774. Targeting the inactive conformation transforms a simple binding event into a sustained pharmacological intervention.

*Internal Map:* 
The logical architecture of this inhibition relies on a "switch-clamp-latch" regulatory mechanism. The primary ligand core anchors to the hinge region, establishing a critical hydrogen bond between the quinazoline N1 and the main chain NH of Met769. Concurrently, the extended tail penetrates the DFG motif (Asp831, Phe832) region, locking the activation loop into a Src-like inactive state. This structural rearrangement allows residues 971 to 980 of the COOH-terminal tail to form a helical segment that packs against the hinge, acting as a physical clamp that restricts further conformational mobility.

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **Bulky benzyloxy-style tails strictly demand the inactive, C-helix shifted conformation.** | GW572016's 3-fluorobenzyloxy group requires a ~9 Å outward shift of the C-helix to form the necessary back pocket, occupying the space previously held by Met742 in the active state. | | High (Validated by 2.40 Å X-ray diffraction data) | The user's benzyloxy tail shares identical spatial requirements to the 3-fluorobenzyloxy moiety. | Small-molecule inhibitors (like OSI-774/Tarceva) bind the active-like state without displacing the C-helix. |
| **The conserved Glu738-Lys721 salt bridge must be broken to accommodate bulky ligands.** | The C-helix displacement abolishes this critical interaction, re-routing Lys721 to form a hydrogen bond with Asp831 in the lower lobe. | | High | Breaking this salt bridge is thermodynamically compensated by the extensive hydrophobic contacts of the bulky tail. | Active-state inhibitors strictly require the maintenance of the Glu738-Lys721 salt bridge for high affinity. |
| **Slow dissociation rates dictate prolonged biological efficacy.** | The inactive-state complex exhibits a 300-minute half-life, which correlates directly with 96-hour suppression of EGFR phosphorylation in HN5 cells. | | High | In vitro dissociation kinetics directly govern in vivo receptor autophosphorylation recovery rates. | Rapid off-rate inhibitors (OSI-774) still achieve high initial apoptosis despite 24-hour phosphorylation recovery. |
| **Inactive-state binding enables dual EGFR/ErbB-2 selectivity.** | GW572016 inhibits both EGFR (Ki 3 nM) and ErbB-2 (Ki 13 nM) identically. The shared ability to adopt this specific inactive conformation drives this dual profile. | | Medium | ErbB-2 cannot readily adopt the active-like conformation required by highly selective EGFR inhibitors. | Selective ErbB-2 inhibitors (CP-654577) exist, indicating alternative mechanisms for specific subtype targeting. |

**Synthesis:**
The prevailing counterposition assumes that active-state structures represent the optimal universal templates for kinase docking protocols. This premise fails because it ignores the profound steric limitations of the DFG-in/alpha-C-in conformation. Attempting to dock your bulky azaborolidine and dioxaborinine compounds into an active-state model will force the structural appendages into insurmountable steric clashes, artificially inflating the interaction energy. This conclusion would be invalidated if your derivative demonstrates sub-nanomolar affinity in a confirmed active-state crystal structure without inducing a C-helix displacement. 

**Dispositive Closure:**
When executing *in silico* docking for your specific boron-containing derivatives against the 1XKK structure, you must explicitly target the expanded back pocket. You are required to assign side-chain flexibility to Met742, Leu753, Thr766, Thr830, Phe832, Leu834, and the Lys721/Asp831 pair. Evaluate poses based strictly on their ability to occupy the volumetric space vacated by the shifted C-helix while preserving the core hinge interaction at Met769. This exact geometrical compliance defines the boundary between functional in silico prediction and artifactual docking failure.

# 5. ERBB2 (7PCD) `A:783, A:805, A:801, A:802`
Ser783, Cys805, Met801, and Pro802
Achieving HER2 selectivity without triggering dose-limiting epidermal growth factor receptor (EGFR) toxicity presents a profound structural paradox. 

**Layer 1 — Core Insight**
The 7PCD crystal structure resolves this paradox by exploiting a single amino acid variance in the hydrophobic back pocket. Highly selective inhibitors penetrate this space to engage Ser783, a residue uniquely present in HER2 compared to the homologous Cys775 in EGFR. To successfully dock your bulky, non-covalent azaborolidine and dioxaborinine derivatives, algorithms must exploit this specific selectivity filter while neutralizing the covalent constraints of the 7PCD template.

**Layer 2 — Structural Explanation (Adaption-Tier Flexible Residues)**
The 7PCD structure represents a covalently locked state. Your compounds lack an acrylamide warhead, mandating an adaption-tier protocol to define dynamic coordinates. First, you must assign flexibility to **Ser783**. This residue acts as the absolute selectivity determinant; its side-chain must rotate to accommodate your extended benzyloxy-methoxybenzyl tail within the back pocket. Second, mandate flexibility for **Cys805**. In 7PCD, Cys805 covalently binds the ligand, but for your massive boronic structures, this front-pocket residue must shift to prevent artifactual collision penalties. Third, establish plasticity at the hinge anchors **Met801** and **Pro802**. These residues must independently adjust to permit optimal hydrogen-bonding alignments with your heterocycles. 

**Layer 3 — Full Technical Detail**

*External Map:* 
In the broader therapeutic landscape, pan-ERBB inhibitors fail because EGFR inhibition drives severe toxicity before HER2 exon 20 insertion mutations are adequately suppressed. Targeting Ser783 bridges this therapeutic gap, allowing profound tumor regression without collateral wild-type EGFR impairment.

*Internal Map:* 
The logical architecture relies on anchoring the heterocyclic core at the Met801/Pro802 hinge while driving a rigid extension into the back pocket. Disruption of either the covalent anchor (via a Cys805Ser mutation) or the back-pocket anchor (via a Ser783Cys mutation) structurally abolishes inhibitor efficacy. 

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **HER2 selectivity exclusively depends on back-pocket Ser783 engagement.** | A Ser783Cys mutation in HER2 eliminates inhibitor potency, while the reverse Cys775Ser mutation in EGFR drastically increases it. | Wilding et al., 2022 | High | The user's benzyloxy tail possesses sufficient length and appropriate geometry to penetrate the back pocket. | Ligands that fail to reach the back pocket cannot utilize this selectivity filter and act as pan-ERBB inhibitors. |
| **Cys805 governs front-pocket affinity and resistance mechanics.** | Cys805Ser mutations emerge as the dominant resistance mechanism against targeted covalent inhibitors during ENU mutagenesis screens. | Wilding et al., 2022 | High | Bulky boronic components occupy the exact spatial volume previously held by the acrylamide warhead. | Non-covalent inhibitors targeting allosteric pockets bypass Cys805 dependency entirely. |
| **Exon 20 insertion efficacy does not require mutant-specific docking templates.** | Wild-type HER2 surrogate structures (7PCD) accurately predict the binding efficacy of inhibitors tested against aggressive HER2YVMA exon 20 insertion mutants. | Wilding et al., 2022 | High | The wild-type ATP-cleft geometry structurally mirrors the functional state of the hyperactive exon 20 insertion mutant. | Specific exon 20 insertions could radically deform the alpha-C helix, invalidating the wild-type template. |

**Synthesis:**
The prevailing counterposition assumes that overcoming EGFR-mediated toxicity requires abandoning the highly conserved ATP-binding cleft in favor of allosteric sites. This premise fails because it ignores the profound discriminative power of the Ser783/Cys775 micro-variance. This conclusion would be invalidated if your bulky azaborolidine derivatives fully occlude the front pocket without penetrating the back pocket, rendering the Ser783 selectivity filter irrelevant. 

**Dispositive Closure:**
When executing *in silico* docking against 7PCD, you must explicitly disable any covalent bonding parameters. Mandate side-chain flexibility for Ser783, Cys805, Met801, and Pro802. Direct your extended benzyloxy appendages strictly into the back pocket toward Ser783. This exact geometrical compliance defines the absolute boundary between dose-limiting EGFR cross-reactivity and highly selective HER2 modulation.

# 6. KDR (5EW3) `A:916, A:919, A:885, A:1046`

Designing selective kinase inhibitors with exceptionally large, boron-containing heterocycles presents a profound steric paradox when targeting vascular endothelial growth factor receptor 2 (VEGFR2). 

**Layer 1 — Core Insight**
The 5EW3 crystal structure demonstrates that resolving this paradox requires exploiting the inactive "DFG-out" conformation of the kinase domain. Highly potent ligands achieve selectivity by leveraging the specific volumetric space afforded by the small gatekeeper residue Val916, avoiding the steric clashes that preclude binding in homologous kinases. To achieve valid docking poses for your extended azaborolidine and dioxaborinine derivatives, algorithms must explicitly target this inactive topology.

**Layer 2 — Structural Explanation (Literature-Tier Flexible Residues)**
The crystallographic and modeling data from the discovery of BAW2881 and AAL993 explicitly identify the dynamic coordinates required to accommodate bulky ligands. When configuring your docking grids for your massive benzyloxy and dioxaborinine scaffolds, you must mandate side-chain plasticity for the following literature-verified residues:
*   **Val916 (Gatekeeper):** This residue dictates absolute target selectivity. It provides the necessary spatial tolerance for bulky aromatic cores (like your 4-(benzyloxy)-3-methoxybenzyl group). If docked against homologous kinases like FLT3, the homologous Phe691 causes a severe steric clash. 
*   **Cys919 (Hinge Anchor):** Acts as the primary hinge-binding motif, forming critical bidentate hydrogen bonds with heterocycles (such as aminopyrimidines or potentially your azaborolidine/dioxaborinine rings).
*   **Glu885 & Asp1046:** These residues coordinate the extended deep pocket unique to the "DFG-out" inactive conformation.
*   **Ile1025 & His1026 (Adaption-Tier):** The backbone carbonyls of these residues form bifurcated hydrogen bonds with solvent-exposed extensions (e.g., piperazinyl groups). If your compounds possess extended polar tails, flexibility here prevents artifactual collision penalties. 

**Layer 3 — Full Technical Detail**

*External Map:* 
In the broader therapeutic landscape, angiogenesis driven by the VEGF/VEGFR system promotes tumor growth and metastasis. Targeting VEGFR2 with high selectivity starves the tumor microenvironment without triggering the broad toxicity profiles associated with unselective multi-kinase inhibitors. 

*Internal Map:* 
The logical architecture of VEGFR2 inhibition relies on anchoring the heterocyclic core at the Cys919 hinge while driving a rigid, bulky extension past the Val916 gatekeeper. Disruption of this spatial mapping, either by targeting the active "DFG-in" state or by failing to navigate the gatekeeper boundary, abolishes compound efficacy.

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **VEGFR2 selectivity strictly depends on the spatial tolerance of the gatekeeper residue.** | The small Val916 gatekeeper in VEGFR2 accommodates bulky naphthyl cores. The homologous, bulkier Phe691 in FLT3 causes an insurmountable steric clash, abolishing activity. | | High | The user's benzyloxy tail requires equivalent or greater volumetric space than the naphthyl core of BAW2881. | Ligands with minimal extensions do not interact with the gatekeeper and bind promiscuously across multiple kinases. |
| **Bulky kinase inhibitors mandate the inactive "DFG-out" conformation.** | AAL993 and BAW2881 bind the inactive "DFG-out" state, requiring specific hydrogen bonds with Cys919, Glu885, and Asp1046 to stabilize the complex. | | High | The massive dioxaborinine structures cannot physically fit within the sterically constrained "DFG-in" active state. | Classical Type 1 inhibitors bind the active conformation directly at the ATP site without requiring the DFG motif to shift. |
| **Targeting conserved backbone interactions degrades kinase selectivity.** | Expanding the inhibitor to form bifurcated hydrogen bonds with the backbone carbonyls of Ile1025 and His1026 retained affinity but drastically reduced kinase selectivity. | | High | Selectivity requires targeting sequence-variant side-chains (like Val916) rather than highly conserved backbone geometries. | Specific non-covalent or halogen geometries could theoretically overcome conserved backbone promiscuity, though unproven here. |
| **Intracellular drug accumulation drives sub-nanomolar cellular efficacy.** | Despite 4 nM biochemical IC50s, compounds like BFH772 achieve <0.01 nM efficacy in 48-hour cellular proliferation assays due to membrane penetration and intracellular accumulation. | | Medium | The user's boronated compounds possess sufficient lipophilicity to penetrate the cytoplasmic membrane. | High biochemical potency does not translate to cellular efficacy if the compound is subject to rapid efflux pumps. |

**Synthesis:**
The prevailing counterposition assumes that maximizing hydrogen bonds across the kinase pocket guarantees an optimal therapeutic profile. This premise fails because it ignores the structural reality that expanding interactions to conserved backbone segments (Ile1025/His1026) destroys selectivity. This conclusion would be invalidated if your specific boronic configurations target highly variant allosteric sites independent of the ATP-hinge region.

**Dispositive Closure:**
When executing *in silico* docking for your specific azaborolidine and dioxaborinine derivatives against the 5EW3 structure, you must explicitly target the "DFG-out" conformation. Mandate side-chain flexibility for Val916, Cys919, Glu885, and Asp1046. Direct your boron-heterocycle cores toward Cys919 to establish the hinge anchor, and route the bulky 4-(benzyloxy)-3-methoxybenzyl moiety past Val916 into the deep hydrophobic pocket. This exact geometrical compliance defines the absolute boundary between highly selective VEGFR2 modulation and unselective target promiscuity.

# 7. PTGS2 (5KIR) `A:523, A:513,A:90,A:385`
Val523, Arg513, His90, and Tyr385
Designing selective cyclooxygenase-2 (COX-2) inhibitors with exceptionally large, boron-containing heterocycles presents a severe topological paradox when navigating the constrained cyclooxygenase channel. 

**Layer 1 — Core Insight**
The 5KIR crystal structure demonstrates that resolving this paradox and achieving isoform selectivity strictly demands penetration into a specific side pocket. Vioxx achieves this by driving a methyl sulfone moiety past the Val523 gatekeeper to interact with Arg513, occupying a space that increases the active site volume by ~25% compared to COX-1. To achieve valid docking poses for your extended azaborolidine and dioxaborinine derivatives, algorithms must exploit this exact topology.

**Layer 2 — Structural Explanation (Adaption-Tier Flexible Residues)**
The crystallographic literature does not explicitly catalog residues as computationally "flexible," mandating an adaption-tier protocol to define the dynamic boundaries for your bulky molecules. The Vioxx binding pose dictates the required dynamic coordinates. First, mandate side-chain plasticity for **Val523**. This residue acts as the absolute gatekeeper to the side pocket; failure to model its flexibility will artificially penalize your extended benzyloxy or oxaborole units with steric clashes, as it replaces the bulkier Ile523 found in COX-1. Second, establish flexibility for **Arg513** and **His90**. These residues sit at the base of the side pocket and form the only hydrophilic interactions with the inhibitor. Your boronic or oxaborole oxygen atoms must coordinate here. Finally, assign flexibility to **Tyr385**, which extends toward the main channel and must adapt to accommodate the inhibitor's extended phenyl ring (or your 4-(benzyloxy)-3-methoxybenzyl moiety).

**Layer 3 — Full Technical Detail**

*External Map:* 
In the broader therapeutic landscape, selective COX-2 inhibition provides anti-inflammatory efficacy without the gastrointestinal toxicity associated with COX-1 inhibition. However, the withdrawal of Vioxx underscores that the specific chemical architecture penetrating the Val523 pocket fundamentally alters systemic cardiovascular profiles.

*Internal Map:* 
The logical architecture of COX-2 inhibition relies on maximizing hydrophobic contacts within the main channel while projecting a polar anchor into the side pocket. Vioxx makes 42 total contacts, but relies entirely on His90 and Arg513 for hydrophilic anchoring. 

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **COX-2 selectivity strictly requires access to the side pocket via Val523.** | Val523 (replacing Ile523 in COX-1) increases the active site volume by ~25% and provides access to Arg513. Mutating Val523 to Ile abolishes isoform-selective inhibition. | Orlando et al., 2016 | High | The user's dioxaborinine/oxaborole groups possess the correct geometry to bypass Val523 and enter this pocket. | Ligands targeting alternative allosteric sites might achieve selectivity without utilizing the Val523 side pocket. |
| **Binding is overwhelmingly driven by hydrophobic interactions.** | Vioxx makes 42 contacts with the channel. The only hydrophilic interactions occur between the methyl sulfone oxygens and the side-chain N atoms of His90 and Arg513. | Orlando et al., 2016 | High | The user's extended benzyloxy tails possess sufficient lipophilicity to satisfy the main channel's hydrophobic requirements. | Highly polar inhibitors could theoretically engineer novel hydrogen-bonding networks outside the side pocket. |
| **Kinetic parameters, not just static geometry, dictate the magnitude of selectivity.** | Vioxx and celecoxib bind in virtually identical poses, yet Vioxx is ~60-fold more selective. This disparity routes back to slow, tight-binding, multi-step binding and dissociation kinetics. | Orlando et al., 2016 | Medium | Static docking scores accurately approximate the thermodynamics of the multi-step kinetic binding process. | Rapidly reversible inhibitors (like classical NSAIDs) rely primarily on transient spatial occlusion rather than complex kinetics. |
| **Weak electron density does not equate to absent ligand interactions.** | Weaker electron density for Vioxx in monomer B results from higher atomic displacement (B-factors) driven by crystal packing forces, not a lack of drug presence. | Orlando et al., 2016 | High | High B-factors in specific domains accurately reflect transient atomic displacement rather than complete disorder. | Complete absence of electron density for specific moieties indicates failure to bind or complete solvent-exposure. |

**Synthesis:**
The prevailing counterposition assumes that mimicking the static binding pose of Vioxx guarantees equivalent selectivity. This premise fails because it ignores that a 60-fold selectivity difference exists between structurally identical poses (Vioxx vs. celecoxib) due to multi-step binding kinetics. This conclusion would be invalidated if your specific boronic configurations target highly variant allosteric sites entirely independent of the cyclooxygenase channel.

**Dispositive Closure:**
When executing *in silico* docking for your specific azaborolidine and dioxaborinine derivatives against the 5KIR structure, you must explicitly target the COX-2 specific side pocket. Mandate side-chain flexibility for Val523, Arg513, His90, and Tyr385. Direct your oxygen-rich boronic/oxaborole moieties past Val523 toward Arg513 and His90 to establish the polar anchor. Concurrently, route the bulky 4-(benzyloxy)-3-methoxybenzyl moiety up toward Tyr385 into the hydrophobic main channel. This exact geometrical compliance defines the absolute boundary between highly selective COX-2 modulation and unselective binding failure.

# 8. PTGES (5EW3) `B:28,B:32,B:52,B:53,A:130,A:134`
Arg52, His53, Thr131, Tyr130, and Ile32
Designing selective therapeutics for microsomal prostaglandin E synthase-1 (mPGES-1) requires navigating a complex trimeric interface where ligands must bridge adjacent protein chains while resting directly above a glutathione (GSH) cofactor. 

The 5TL9 crystal structure demonstrates that resolving the spatial requirements of bulky ligands demands interfacial plasticity. Ligands achieve high affinity by anchoring at the cleft opening and projecting rigid extensions down shallow flanking grooves formed by adjacent monomers. The prevailing assumption that static docking against a single protein chain yields accurate predictions fails entirely here. Because mPGES-1 is a homotrimer, the active site resides squarely at the interface of two chains. Your prior strategy of selecting flexible residues across multiple chains (Chain A and Chain B) is not merely correct; it constitutes a structural mandate for this target. This conclusion would be invalidated only if your ligands target an uncharacterized, completely monomeric allosteric pocket.

To accommodate your massive azaborolidine and dioxaborinine derivatives, your docking protocol must model the dynamic shifts of specific boundary residues. We extract the following flexible residues from the 5TL9 structure:

**Literature-Tier Flexible Residues:**
*   **Arg52 and His53 (Chain A):** These residues form the critical bidentate salt-bridge and hydrogen-bond network at the pocket opening. Your oxygen-rich boronic heterocycles will compete for this exact coordination space.

**Adaption-Tier Flexible Residues:**
*   **Thr131 and Ser127 (Chain B):** Located on the adjacent chain (forming the opposite wall of the flanking groove), these residues coordinate ordered water molecules. They must shift to prevent artifactual collision penalties with your extended benzyloxy appendages.
*   **Tyr28, Ile32, Tyr130, and Gln134:** These residues define the deep hydrophobic cleft. Your bulky 4-(benzyloxy)-3-methoxybenzyl moiety demands volumetric expansion here. Ile32 specifically forms a deep sub-pocket that bulky methyl or aromatic groups penetrate.

*External Map:* Traditional NSAIDs and COX-2 inhibitors carry severe cardiovascular risks due to the indiscriminate suppression of prostacyclin (PGI2). Targeting mPGES-1 circumvents this toxicity by selectively inhibiting inducible PGE2 formation without disrupting collateral prostanoid pathways.
*Internal Map:* Optimization of the 5TL9 ligand (compound 16) relied entirely on translating cell-free enzymatic affinity into the Human Whole Blood (HWB) assay. Furthermore, mitigating off-target CYP2C9 inhibition required strict control of lipophilicity within the hydrophobic core.

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **The mPGES-1 active site mandates multi-chain interface docking.** | The co-crystal structures explicitly demonstrate ligands interacting simultaneously with residues from "Chain 1" (Arg52, His53) and "Chain 2" (Ser127, Thr131). | Partridge et al., 2017 | High | A single monomer lacks the topological boundary required to form a complete, functional binding pocket. | Extremely small fragments might theoretically bind superficially to a single monomer without bridging the trimeric interface. |
| **HWB PGE2 reduction defines the absolute metric for clinical translation.** | Inhibition of PGE2 production at the IC80 level in human whole blood directly correlates with efficacious *in vivo* plasma drug concentrations. | Partridge et al., 2017 | High | *In vitro* cell-free assays fail to capture physiological protein binding, cellular penetration, and membrane partition dynamics. | Nanomolar enzymatic inhibitors (e.g., compound 5, IC50 = 43 nM) frequently demonstrate severe efficacy drop-offs in HWB environments (IC50 = 8.91 µM). |
| **Non-planar central constraints optimize groove trajectory.** | Replacing a central aromatic core with a five-membered aliphatic cyclopentane allowed the specific projection of substituents down the right-hand hydrophobic groove. | Partridge et al., 2017 | Medium | The user's dioxaborinine and azaborolidine rings possess sufficient non-planar geometry to mimic this highly specific trajectory. | Highly flexible, unconstrained aliphatic chains incur an insurmountable entropic penalty upon binding. |
| **Lipophilicity reduction eliminates off-target CYP2C9 inhibition.** | Modifying the 2-alkylbenzoic acid derivatives to lower the calculated logD (removing halogens) eliminated single-point CYP2C9 inhibition. | Partridge et al., 2017 | Medium | The off-target interaction is driven primarily by nonspecific hydrophobic packing rather than specific coordinate hydrogen bonds. | Compound 9 exhibited lower clearance despite having similar CYP2C9 inhibition to compound 7, proving clearance mechanisms remain multifactorial. |

**Dispositive Closure:**
Configure your docking grid precisely at the interface of Chain A and Chain B, establishing the center directly above the glutathione cofactor. You must assign side-chain flexibility to Arg52, His53, Thr131, Tyr130, and Ile32. Direct your boronic/oxaborole cores toward Arg52/His53 to establish the polar anchor, and force the massive benzyloxy-methoxybenzyl tail down the hydrophobic groove. This specific interfacial compliance defines the boundary between functional *in silico* prediction and systematic docking failure.

# 9. ALOX5 (6NCF) `B:101,B:102,B:130,B:137,B:138,B:165,B:166`
Arg101, Trp102, His130, Thr137, Arg138, Arg165, and Asp166
Designing selective inhibitors for 5-lipoxygenase (5-LOX) presents a profound mechanistic paradox. 

**Layer 1 — Core Insight**
The 6NCF crystal structure demonstrates that resolving this paradox requires abandoning the highly flexible, easily disordered catalytic active site,. Instead, therapeutic selectivity and efficacy demand targeting a discrete allosteric groove wedged between the membrane-binding and catalytic domains,. To achieve valid binding poses for your exceptionally bulky azaborolidine and dioxaborinine derivatives, algorithms must exploit this specific interdomain topology.

**Layer 2 — Structural Explanation**
To accommodate your massive molecular structures within this allosteric pocket, you must model specific interdomain plasticity. The crystallographic literature explicitly identifies **Arg101**, **Trp102**, **Arg165**, and **Asp166** as mandatory dynamic coordinates (Literature-Tier). Allosteric binding physically disrupts the highly conserved Trp102-Arg165 cation-pi interaction and the Arg101-Asp166 salt bridge, which serve as the primary communication links between the two domains. Furthermore, an adaption-tier protocol mandates side-chain flexibility for **His130**, **Thr137**, and **Arg138**. These residues form the critical polar anchors within the groove. Your oxygen-rich boronic and benzyloxy moieties will compete for this exact coordination space. Supplying flexibility here ensures the docking algorithm can model these disrupted electrostatic networks without triggering artifactual collision penalties. 

**Layer 3 — Full Technical Detail**

*External Map:* 
In the broader therapeutic landscape, classical active-site inhibitors like NDGA trigger massive structural disorder, rendering rational drug optimization nearly impossible,,. Shifting the target to the AKBA allosteric site fundamentally reprograms the enzyme. It transforms 5-LOX from a pro-inflammatory leukotriene producer into a 12-lipoxygenating enzyme, thereby promoting the biosynthesis of specialized pro-resolving mediators (SPMs) that actively resolve inflammation,,.

*Internal Map:* 
The logical architecture of this inhibition relies on anchoring the ligand lengthwise within the interdomain crevice. Occupying this space mechanically alters the distant catalytic site by increasing the thermal mobility of the Phe177/Tyr181 aromatic cork. This structural uncoupling physically restricts 5-LOX from accessing its most productive leukotriene-generating conformations. 

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence (Low/Medium/High) | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **The 5-LOX interdomain groove provides the optimal site for rational drug design.** | Unlike the active site, the allosteric groove remains structurally stable upon ligand binding. AKBA buries 80% of its surface area here without inducing extensive peptide disorder. | Gilbert et al., 2020, | High (Backed by 3.0 Å X-ray diffraction data for 6NCF) | The user's bulky boron compounds possess sufficient lipophilicity to exploit this deep interdomain crevice. | NDGA binds the active site and completely ablates enzyme activity, whereas AKBA only functions as a noncompetitive partial inhibitor. |
| **Allosteric binding disrupts conserved interdomain communication.** | AKBA binding explicitly breaks the Trp102-Arg165 cation-pi interaction and the Arg101-Asp166 salt bridge, increasing the thermal mobility (B-factors) of the active-site cork (Phe177/Tyr181). | Gilbert et al., 2020, | High | Mechanical disruption of these specific salt bridges is required to transmit the allosteric signal to the active site. | Mutations that pre-break these links (R101A) still allow AKBA binding, indicating the disruption is a consequence, not a prerequisite, of binding. |
| **Allosteric modulation shifts 5-LOX regiospecificity.** | AKBA reduces 5-HETE and LTB4 production but significantly increases 12-HETE production in intact cells, reprogramming the enzyme's catalytic attack from C(7) to C(10). | Gilbert et al., 2020,,, | High | The shift to 12-HETE production directly translates into the generation of anti-inflammatory specialized pro-resolving mediators (SPMs). | Co-incubation with the active-site inhibitor zileuton completely abolishes this AKBA-induced 12-HETE formation. |
| **Active-site targeted antioxidants induce insurmountable structural disorder.** | NDGA binding requires the Phe177/Tyr181 corking residues to displace, causing massive unresolvable disorder across helices shielding the active site. | Gilbert et al., 2020, | High | The disorder observed in the crystal lattice directly mirrors the physiological conformational state of the NDGA-inhibited enzyme. | The disorder may be an artifact of the specific Stable-5-LOX mutations combined with crystal packing forces. |

**Synthesis:**
The prevailing counterposition assumes that 5-LOX inhibition strictly requires direct physical occlusion of the catalytic iron within the active site. This premise fails because it ignores the structural reality that the allosteric interdomain groove uniquely dictates the enzyme's regiospecificity and dynamic stability,. Attempting to force your massive azaborolidine and dioxaborinine compounds into the closed active site will force the structural appendages into insurmountable steric clashes. This conclusion would be invalidated if your derivatives bypass the interdomain groove entirely and directly access the catalytic iron without inducing the catastrophic disorder observed with NDGA.

**Dispositive Closure:**
When executing *in silico* docking against the 6NCF structure, you must explicitly target the allosteric groove located between the membrane-binding and catalytic domains. You are required to assign side-chain flexibility to Arg101, Trp102, His130, Thr137, Arg138, Arg165, and Asp166. Direct your oxygen-rich boronic heterocycles toward His130, Arg101, and Thr137 to establish the necessary polar anchors, while routing the bulky 4-(benzyloxy)-3-methoxybenzyl moiety along the hydrophobic surfaces provided by Leu66 and Val110. This exact geometrical compliance defines the absolute boundary between functional allosteric modulation and artifactual docking failure.
